Cambridge, UK, 29 July 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or “the Company”), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today provides an unaudited pre-close trading update for the six months ended 30 June 2020. The Company plans to report its half year 2020 results on 17 August 2020.
Financials